Cargando…

Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2− subtype breast cancer

Luminal breast cancers (BC) account for majority of breast cancer. Due to its heterogeneity and the development of treatment resistance, luminal BC patients can vary substantially. Long noncoding RNAs (lncRNAs), as we known, is involved in breast cancer progression. Here, we aim to identify the lncR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Lei, Chi, Yayun, Chen, Jiajian, Xue, Jingyan, Deng, Linlin, Huang, Naisi, Shao, Jianghua, Wu, Jiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620366/ https://www.ncbi.nlm.nih.gov/pubmed/28959047 http://dx.doi.org/10.1038/s41598-017-11066-7

Ejemplares similares

Breast Sclerosing Adenosis and Accompanying Malignancies: A Clinicopathological and Imaging Study in a Chinese Population
por: Huang, Naisi, et al.
Publicado: (2015)

Overexpression of Long Non-Coding RNA Linc01315 Predicts Poor Prognosis in Breast Cancer
por: Xue, Jingyan, et al.
Publicado: (2021)

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
por: Wang, Wei, et al.
Publicado: (2023)

The BMP inhibitor DAND5 in serum predicts poor survival in breast cancer
por: Chi, Yayun, et al.
Publicado: (2016)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer
por: Wang, Long, et al.
Publicado: (2021)

Stabilization of CCDC102B by Loss of RACK1 Through the CMA Pathway Promotes Breast Cancer Metastasis via Activation of the NF-κB Pathway
por: Si, Jing, et al.
Publicado: (2022)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

Role of BC040587 as a predictor of poor outcome in breast cancer
por: Chi, Yayun, et al.
Publicado: (2014)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients
por: Guo, Liang, et al.
Publicado: (2017)

Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2− Early Breast Cancer
por: Ni, Hua, et al.
Publicado: (2021)

Dysregulated Expression of Circular RNAs Serve as Prognostic and Clinicopathological Markers in Cancer
por: Huang, Xin, et al.
Publicado: (2019)

A systematic literature review of prognostic factors in patients with HR+/HER2− advanced breast cancer in Japan
por: Hattori, Masaya, et al.
Publicado: (2021)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription
por: Xiu, Bingqiu, et al.
Publicado: (2019)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Conditional transcriptional relationships may serve as cancer prognostic markers
por: Yu, Hui, et al.
Publicado: (2021)

LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets
por: Guo, Rong, et al.
Publicado: (2023)

Cross-talk of four types of RNA modification proteins with adenosine reveals the landscape of multivariate prognostic patterns in breast cancer
por: Wang, Xuliren, et al.
Publicado: (2022)

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC
por: Zheng, Shuyue, et al.
Publicado: (2022)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2− early breast cancer
por: Gong, Gyungyub, et al.
Publicado: (2017)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
por: Duan, Fangfang, et al.
Publicado: (2021)

Glycosylated Cathepsin V Serves as a Prognostic Marker in Lung Cancer
por: Yang, Lewei, et al.
Publicado: (2022)

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
por: Shao, Bin, et al.
Publicado: (2022)

Development and Validation of a Robust Ferroptosis-Related Gene Panel for Breast Cancer Disease-Specific Survival
por: Li, Pei, et al.
Publicado: (2021)

Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes
por: Orrù, Sandra, et al.
Publicado: (2022)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2022)

HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration
por: Lu, Ying, et al.
Publicado: (2023)

Application file for the EU Charter and Code Award "HR Excellence in Research"
por: Cook, Anna
Publicado: (2018)

EU Charter and Code Award "HR Excellence in Research": Interim Assessment
por: Kerhoas, Anne
Publicado: (2023)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes
por: Yaghi, Marita, et al.
Publicado: (2022)

Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast
por: Vaid, Ashok, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0u5m4f09gkb1hio98kuchts969